UNH vs VYNE

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...

Vyne Therapeutics Inc. (VYNE) presents an extremely high-risk, near-zero reward profile for existing shareholders, solidifying its precarious position since the last analysis. The primary concern is the impending merger with Yarrow Bioscience, where current VYNE shareholders are expected to own only 3% of the combined entity, ensuring near-total value destruction through massive dilution. This pro...